All the novel tribodies were found able to bind to hPBMCs and 5T4-positive tumor cells in a comparable manner or even better than the parental Tb535H, and to retain the binding ability of both the parental mAbs for ICs as well as that of Tb535H for 5T4. Here, TPBG is linked to neoplasm.